Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
| Marina Biotech, Inc. (NASDAQ: MRNA) | Delayed: 236.50 +10.20 (4.51%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $226.30 | 52 Week High | $0.52 | |||
| Open | $225.48 | 52 Week Low | $0.08 | |||
| Day High | $242.29 | P/E | N/A | |||
| Day Low | $217.02 | EPS | $-3.80 | |||
| Volume | 17,357,478 | |||||
